Mr. Adam Berk reports

STEM HOLDINGS LAUNCHES MEDICAL CANNABIS DIVISION

Stem Holdings Inc. has launched Stem Medical Holdings (SMH), a new division focused on cannabidiol (CBD), an active ingredient in cannabis. SMH will develop, produce and market exclusive medical CBD products initially for dermatology and gerontology, with plans to penetrate additional medical product markets.

In its July, 2019, report, Brightfield Group, a research firm focused on the legal CBD and cannabis industries, estimates the United States CBD market will grow over 700 per cent in 2019 to $5-billion from $620-million in 2018 and reach $23.7-billion by 2023.

Drore Eisen, doctor of medicine, doctor of dental surgery, will oversee the newly formed SMH division, as medical director, bringing more than 30 years of medical experience to the role. Fusing Stem's proprietary cannabis strains cultivated for quality and efficacy for many years with the world-class research and expertise of Dr. Eisen, SMH intends to create and market medical CBD products consistent with Stem's mission and standards of supporting the health and happiness of people

"We are very pleased to welcome Dr. Eisen and to launch Stem Medical Holdings to serve this market with unique products," said Adam Berk, chief executive officer of Stem. "Dr. Eisen brings decades of experience in the dermatology and gerontology fields. We are confident that he will lead our medical division to further position and drive growth for Stem as a pioneer in the industry with differentiated medical cannabis offerings that appeal to all consumers seeking its medical benefits."

Dr. Eisen has practiced dermatology for more than 30 years, including serving as co-director of Dermatology Research Associates in Cincinnati, Ohio, from 1990 to 2014. Dr. Eisen has served as a principal investigator, or co-investigator, in over 80 clinical trials. As a consultant to many major and start-up pharmaceutical companies, Dr. Eisen has been instrumental in developing study design, writing protocols and educating other physicians about medical products. He has also played a key role in the clinical expansion of Procter & Gamble's oral prescription care products by developing clinical protocols and managing all national and international clinical trials. His background in dentistry, combined with dermatology, enhanced his contributions in these areas.

"I am honoured to join Stem's advisory team as the medical director of Stem Medical Holdings," stated Dr. Eisen. "Stem has firmly established itself as a pioneer in the cannabis industry with a robust portfolio of brands and products for medical applications. I am excited to have the opportunity to bring my experience in treatment and research to advance Stem's medical cannabis R&D and product development in order to help patients and to position Stem as a leader in this field," he concluded.

About Dr. Eisen

Dr. Eisen is a well-known and honoured dermatologist, who has practiced dermatology for over three decades after graduating from the Medical College of Virginia. He is also a doctor of dental surgery, having first completed his undergraduate work at Columbia University. In addition to his work in product development and clinical testing, Dr. Eisen has collaborated on cancer research projects with the National Cancer Institute and, as a sought after medical expert, he chaired the oral diseases symposium at the American Academy of Dermatology annual meeting for six years, presenting numerous lectures. He also has served as a visiting professor at local, state, national and international meetings. He has co-authored two textbooks and over 50 articles on medical diseases, including publications in The New England Journal of Medicine and The Lancet. Dr. Eisen was recognized as a best doctor by Cincinnati Magazine from 1997 to 2019 and is the recipient of numerous awards, including the American Academy of Dermatology's Educational Leadership Award and the Mayo Clinic's Harold O. Perry Lecture Award.

About Stem Holdings Inc.

As a vertically integrated cannabis company, Stem has positioned itself as a pioneer in the industry with its state-of-the-art cultivation, processing, extraction, retail and distribution operations. Stem owns cannabis facilities in Nevada, Oklahoma and Oregon and also participates in a research project in collaboration with Cornell University. Utilizing proprietary, sustainable cultivation techniques, Stem develops exceptional products that are safe and comprise lab-tested cannabis and CBD.

We seek Safe Harbor.